Finch Therapeutics Group (NASDAQ:FNCH) versus Inhibikase Therapeutics (NYSE:IKT) Head-To-Head Comparison

Inhibikase Therapeutics (NYSE:IKTGet Rating) and Finch Therapeutics Group (NASDAQ:FNCHGet Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Institutional and Insider Ownership

24.5% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 22.7% of Finch Therapeutics Group shares are held by institutional investors. 55.8% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Inhibikase Therapeutics and Finch Therapeutics Group’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inhibikase Therapeutics $3.10 million 5.78 -$14.79 million ($0.86) -0.83
Finch Therapeutics Group $18.53 million 5.44 -$58.16 million ($1.93) -1.10

Inhibikase Therapeutics has higher earnings, but lower revenue than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Inhibikase Therapeutics and Finch Therapeutics Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inhibikase Therapeutics -476.81% -43.28% -39.58%
Finch Therapeutics Group -313.84% -26.15% -23.87%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Inhibikase Therapeutics and Finch Therapeutics Group, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibikase Therapeutics 0 0 1 0 3.00
Finch Therapeutics Group 0 0 1 0 3.00

Inhibikase Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 1,590.38%. Finch Therapeutics Group has a consensus price target of $17.00, indicating a potential upside of 709.52%. Given Inhibikase Therapeutics’ higher probable upside, equities analysts clearly believe Inhibikase Therapeutics is more favorable than Finch Therapeutics Group.

Volatility & Risk

Inhibikase Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.


Inhibikase Therapeutics beats Finch Therapeutics Group on 7 of the 11 factors compared between the two stocks.

Inhibikase Therapeutics Company Profile (Get Rating)

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Finch Therapeutics Group Company Profile (Get Rating)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with's FREE daily email newsletter.